GlassScriptPhysician profile
Vikram C Gorantla
NPI 1528220779
$61,679.74
in general payments reported to CMS, 2019-2025
19 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,559 · 2021: $294 · 2022: $5,337 · 2023: $16K · 2024: $10K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Food and Beverage: $1,779 · Travel and Lodging: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,220.00 |
| Food and Beverage | $1,778.94 |
| Travel and Lodging | $789.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,987.25 | 2019-2025 | Enhertu, Lynparza |
| Siemens Medical Solutions USA, INC. | $15,000.00 | 2023-2025 | |
| Stemline Therapeutics INC. | $7,500.12 | 2022-2025 | Orserdu |
| Avyxa Pharma, LLC | $5,000.00 | 2024 | |
| Mylan Institutional INC. | $4,166.77 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $3,875.44 | 2019 | |
| Exelixis INC. | $2,842.57 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $1,635.22 | 2019 | |
| R-Pharm US LLC | $1,320.28 | 2019 | |
| Gilead Sciences, INC. | $1,283.18 | 2021-2025 | Trodelvy |
| Athenex Pharmaceutical Division, LLC | $1,250.00 | 2020 | |
| Celgene Corporation | $250.27 | 2019-2024 | Pomalyst |
| Pfizer INC. | $247.98 | 2020-2021 | |
| Genentech, INC. | $119.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $93.63 | 2022-2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $48.80 | 2020 | |
| Eisai INC. | $42.09 | 2023 | |
| Tempus Ai, INC | $16.63 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Gorantla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.